Novel Inhibitors for the Treatment of Highly Drug-Resistant Chronic Myelogenous

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$149,616.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA139771-01
Award Id:
93546
Agency Tracking Number:
CA139771
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
HOUSEY PHARMACEUTICAL RESEARCH LAB, 16800 W 12 MILE RD, STE 201, SOUTHFIELD, MI, 48076
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
611659819
Principal Investigator:
GERARD HOUSEY
(248) 663-7000
GHOUSEY@HOUSEY.COM
Business Contact:
MITCHELL HOUSEY
() -
ghousey@housey.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): This is the Phase 1 application of an SBIR proposal entitled Novel Inhibitors for the Treatment of Highly Drug Resistant Chronic Myelogenous Leukemia. The overall goal of this proposal is to test the efficacy of a cla ss of novel small molecule scaffolds, which have been discovered and developed by HPRL, in a mouse model of leukemia. A secondary goal is to further optimize two or three of the best lead candidates for cellular specificity and oral bioavailability. All of the HPRL compounds relevant to this proposal are nanomolar inhibitors of the T315I mutant of the BCR-ABL oncogene product, an oncoprotein which is of central importance in the develompent of chronic myelogenous leukemia (CML). The NIH support will be use d to focus research at Housey Pharmaceutical Research Laboratories (hereinafter HPRL ) to further develop and commercialize discoveries originally made in the laboratories of Dr. Charles Sawyers, M.D., at the University of California at Los Angeles (UCLA) , Los Angeles, CA, which have been exclusively licensed to HPRL for therapeutic applications. This Phase I proposal builds upon the solid scientific foundation established by Dr. Sawyers and his colleagues while at UCLA. Dr. Sawyers is now the Chairman of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center and serves as HPRL's Principal Scientific Advisory Board member and Senior Consultant with respect to this therapeutic program. Over the past eight years Dr. Sawyers a nd his colleagues, including Dr. Neil Shah, M.D. (now at UCSF), have made seminal discoveries surrounding the development of resistance to imatinib mesylate (Gleevec), a medicine which has revolutionized the treatment of chronic myelogenous leukemia (CML). They have also made key contributions to the development of dasatinib (Sprycel), a compound which is capable of treating some, but not all, of the BCR-ABL mutations that emerge in CML patients who eventually develop imatinib resistance. The proposal prov ides the unique opportunity to further develop and commercialize key intellectual property and technology originally created by NIH-supported scientists at the University of California at Los Angeles (UCLA), the Memorial Sloan Kettering Cancer Center (MSK CC), and the University of California at San Francisco (UCSF) who are acknowledged leaders in the field. The proposal brings together the academic expertise of leaders in the field of imatinib resistance with Housey Pharmaceutical Research Laboratories ( HPRL), an organization whose scientists have a strong track record of creating, developing and commercializing intellectual property and technology of formidable market value. Cell-based assay technology originally developed by Housey scientists has been licensed and is in use at the majority of the world's best research-driven pharmaceutical concerns. PUBLIC HEALTH RELEVANCE: Development of novel therapeutic agents for the treatment of drug-resistant chronic myelogenous leukemia and other forms of cancer.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government